Cited 5 times in
The optimal morning: evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24-week multi-centre prospective, randomized controlled, open-labelled clinical study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이용호 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2015-01-06T16:30:36Z | - |
dc.date.available | 2015-01-06T16:30:36Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0742-3071 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98240 | - |
dc.description.abstract | AIMS: Biphasic insulin analogues are widely used in patients with Type 2 diabetes mellitus suboptimally controlled on oral anti-diabetic drugs. Several topics in this area remain controversial, including how to divide the daily dose of biphasic insulin analogue. We aimed to determine the optimal dosing ratio of twice-daily biphasic insulin analogue and to compare the glycaemic efficacy among groups of patients using different initial dosing ratios of biphasic insulin analogue. METHODS: A total of 100 poorly controlled insulin-naive subjects with Type 2 diabetes [HbA1c ≥ 58 mmol/mol, (7.5%)] on oral anti-diabetic drugs were randomized into three groups according to initial morning:evening dosing ratio (group I, 50:50; group II, 55:45; group III, 60:40) of twice-daily biphasic insulin analogue (biphasic insulin aspart 70/30, biphasic insulin aspart 30). The primary outcome measure was the difference in pre-breakfast to pre-dinner dose ratio at the end of the study. RESULTS: Twice-daily biphasic insulin analogue showed a significant improvement in glycaemic control [HbA1c from 70 mmol/mol (8.6%) to 60 mmol/mol (7.6%)] after 24 weeks regardless of the initial dose ratio given. Despite the similar efficacy and safety profiles among three groups, morning dose was significantly increased (from 50:50 to 55:45-60:40) in group I after 24 weeks. However, there was no significant change in splitting ratio in groups II and III (with higher morning dose) over the 24-week treatment period. CONCLUSIONS: These results indicate that initiating twice-daily biphasic insulin analogue on regimens with a higher dose before breakfast than before dinner (i.e. ratio approximately 55:45 to 60:40) might be more appropriate in Korean subjects with Type 2 diabetes. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 68~75 | - |
dc.relation.isPartOf | DIABETIC MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Biphasic Insulins/administration & dosage* | - |
dc.subject.MESH | Biphasic Insulins/pharmacokinetics | - |
dc.subject.MESH | Blood Glucose/drug effects* | - |
dc.subject.MESH | Blood Glucose/metabolism | - |
dc.subject.MESH | Blood Glucose Self-Monitoring | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/drug therapy* | - |
dc.subject.MESH | Diabetes Mellitus, Type 2/metabolism | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glycated Hemoglobin A/drug effects* | - |
dc.subject.MESH | Glycated Hemoglobin A/metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents/administration & dosage* | - |
dc.subject.MESH | Hypoglycemic Agents/pharmacokinetics | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | The optimal morning: evening ratio in total dose of twice-daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24-week multi-centre prospective, randomized controlled, open-labelled clinical study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | C. H. Jung | - |
dc.contributor.googleauthor | J.-Y. Park | - |
dc.contributor.googleauthor | J. H. Cho | - |
dc.contributor.googleauthor | K.-H. Yoon | - |
dc.contributor.googleauthor | H. K. Yang | - |
dc.contributor.googleauthor | Y.-H. Lee | - |
dc.contributor.googleauthor | B. S. Cha | - |
dc.contributor.googleauthor | B.-W. Lee | - |
dc.identifier.doi | 10.1111/dme.12322 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J00726 | - |
dc.identifier.eissn | 1464-5491 | - |
dc.identifier.pmid | 24118113 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/dme.12322/abstract | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.alternativeName | Lee, Yong Ho | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | Lee, Yong Ho | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 31 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 68 | - |
dc.citation.endPage | 75 | - |
dc.identifier.bibliographicCitation | DIABETIC MEDICINE, Vol.31(1) : 68-75, 2014 | - |
dc.identifier.rimsid | 50740 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.